Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

Introduction: Evaluation of health-related quality-of-life (HRQoL) and symptom improvement were preplanned secondary objectives for the overall population and posthoc analyses for epidermal growth factor receptor (EGFR) mutation-positive/negative subgroups in IPASS. Methods: HRQoL was assessed using...

Saved in:

書目詳細資料
Main Authors:	Sumitra Thongprasert, Emma Duffield, Nagahiro Saijo, Yi Long Wu, James Chih Hsin Yang, Da Tong Chu, Meilin Liao, Yuh Min Chen, Han Pin Kuo, Shunichi Negoro, Kwok Chi Lam, Alison Armour, Patrick Magill, Masahiro Fukuoka
格式:	雜誌
出版:	2018
主題:	Medicine
在線閱讀:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80054882063&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/50311
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!
機構:	Chiang Mai University

相似書籍

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
由: Thongprasert S., et al.
出版: (2014)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
由: Tony S. Mok, et al.
出版: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
由: Tony S. Mok, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Masahiro Fukuoka, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Wu Y., et al.
出版: (2017)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Fukuoka M., et al.
出版: (2017)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Paclitaxel and Carboplatin in Combination in the Treatment of Advanced Non-small-cell Lung Cancer (NSCLC) : A Preliminary Study
由: Vorachai Ratanatharathorn, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Wu Y.-L., et al.
出版: (2014)

Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
由: Chaiyut Charoentum, et al.
出版: (2018)

Paclitaxel and carboplatin plus megestrol acetate in the treatment of advanced non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
由: Sumitra Thongprasert, et al.
出版: (2018)

Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
由: Charoentum C., et al.
出版: (2014)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
由: Kietpeerakool C., et al.
出版: (2014)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
由: Chumnan Kietpeerakool, et al.
出版: (2018)

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
由: Laksmi Wulandari, -, et al.
出版: (2022)

Symptom Clusters in Thai Gynecological Oncology Patients Receiving the First Cycle of Carboplatin and Paclitaxel
由: Bualuang Sumdaengrit, et al.
出版: (2022)

Remission of recurrent cervical cancer with paclitaxel and carboplatin: A case report and review of literature
由: W. Termrungruanglert, et al.
出版: (2018)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

The Comparison of Neutropenia and Peripheral Neuropathy Condition as an Impact of 3-hours and 24-hour Paclitaxel Infusion of Paclitaxel-Carboplatin Chemotherapy on Ovarian Cancer Patients
由: Primandono Perbowo, -, et al.
出版: (2019)

Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer
由: Kietpeerakool C., et al.
出版: (2014)

Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer
由: Chumnan Kietpeerakool, et al.
出版: (2018)

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
由: Reungwetwattana T.
出版: (2023)

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
由: Tan, Eng-Huat, et al.
出版: (2022)

Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy
由: Chumnan Kietpeerakool, et al.
出版: (2018)

Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy
由: Chumnan Kietpeerakool, et al.
出版: (2018)

Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy
由: Kietpeerakool C., et al.
出版: (2014)

Effects of paclitaxel and carboplatin on quality of life and survival in patients with advanced non-small-cell lung cancer
由: Vorachai Ratanatharathorn, et al.
出版: (2018)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
由: Wong, A.S., et al.
出版: (2014)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Chee Khoon Lee, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Chee Khoon Lee, et al.
出版: (2018)

Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
由: Daranee Sirichaisutdhikorn, et al.
出版: (2018)

Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
由: Ratanatharathorn V., et al.
出版: (2014)

Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
由: Daranee Sirichaisutdhikorn, et al.
出版: (2018)

Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
由: Sirichaisutdhikorn D., et al.
出版: (2014)

Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
由: Sirichaisutdhikorn D., et al.
出版: (2014)